Sphera Funds Management LTD. Acquires New Position in Audentes Therapeutics Inc (BOLD)

Share on StockTwits

Sphera Funds Management LTD. acquired a new stake in shares of Audentes Therapeutics Inc (NASDAQ:BOLD) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 120,000 shares of the biotechnology company’s stock, valued at approximately $4,751,000. Sphera Funds Management LTD. owned about 0.28% of Audentes Therapeutics as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of BOLD. Partner Fund Management L.P. boosted its stake in shares of Audentes Therapeutics by 265.4% during the third quarter. Partner Fund Management L.P. now owns 1,554,139 shares of the biotechnology company’s stock valued at $61,528,000 after acquiring an additional 1,128,757 shares during the last quarter. Redmile Group LLC boosted its stake in shares of Audentes Therapeutics by 70.3% during the second quarter. Redmile Group LLC now owns 2,228,656 shares of the biotechnology company’s stock valued at $85,157,000 after acquiring an additional 920,130 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Audentes Therapeutics by 25.4% during the second quarter. BlackRock Inc. now owns 2,458,171 shares of the biotechnology company’s stock valued at $93,925,000 after acquiring an additional 497,767 shares during the last quarter. Nexthera Capital LP acquired a new stake in shares of Audentes Therapeutics during the second quarter valued at $9,228,000. Finally, Victory Capital Management Inc. boosted its stake in shares of Audentes Therapeutics by 35.1% during the second quarter. Victory Capital Management Inc. now owns 739,241 shares of the biotechnology company’s stock valued at $28,246,000 after acquiring an additional 191,950 shares during the last quarter. 84.48% of the stock is currently owned by institutional investors and hedge funds.

BOLD has been the topic of a number of research analyst reports. Citigroup initiated coverage on Audentes Therapeutics in a research note on Monday, August 20th. They issued a “neutral” rating and a $40.00 price target on the stock. Mizuho reissued a “buy” rating and issued a $45.00 price target on shares of Audentes Therapeutics in a research note on Wednesday, August 22nd. HC Wainwright set a $40.00 price target on Audentes Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, August 22nd. B. Riley initiated coverage on Audentes Therapeutics in a research note on Friday, September 7th. They issued a “sell” rating and a $20.00 price target on the stock. Finally, Cowen initiated coverage on Audentes Therapeutics in a research note on Friday, September 7th. They issued a “sell” rating and a $20.00 price target on the stock. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $35.49.

In other news, CEO Matthew R. Patterson sold 12,952 shares of Audentes Therapeutics stock in a transaction dated Tuesday, September 18th. The stock was sold at an average price of $40.00, for a total value of $518,080.00. Following the transaction, the chief executive officer now directly owns 12,952 shares of the company’s stock, valued at approximately $518,080. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Suyash Prasad sold 10,000 shares of Audentes Therapeutics stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $36.88, for a total value of $368,800.00. Following the completion of the transaction, the vice president now directly owns 100 shares in the company, valued at $3,688. The disclosure for this sale can be found here. Insiders sold a total of 101,039 shares of company stock worth $3,465,020 over the last ninety days. Corporate insiders own 6.60% of the company’s stock.

Shares of NASDAQ:BOLD opened at $23.44 on Friday. Audentes Therapeutics Inc has a 12-month low of $19.62 and a 12-month high of $46.18. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of -6.89 and a beta of 1.89.

Audentes Therapeutics (NASDAQ:BOLD) last released its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.09). During the same quarter last year, the business earned ($0.88) earnings per share. Equities analysts predict that Audentes Therapeutics Inc will post -3.44 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Sphera Funds Management LTD. Acquires New Position in Audentes Therapeutics Inc (BOLD)” was originally posted by BBNS and is owned by of BBNS. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://baseballnewssource.com/2018/12/08/sphera-funds-management-ltd-acquires-new-position-in-audentes-therapeutics-inc-bold/3065374.html.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Featured Story: What is the float in trading stocks?

Want to see what other hedge funds are holding BOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Audentes Therapeutics Inc (NASDAQ:BOLD).

Institutional Ownership by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.